Cybrexa Regains Rights to CBX-12
06 févr. 2024 08h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Cybrexa Therapeutics To Present Data at ASCO 2023 Highlighting First-In-Human, Dose-Finding Study of Lead Candidate CBX-12
25 mai 2023 17h01 HE
|
Cybrexa Therapeutics
Activity and Safety Profile Reinforces Potential of CBX-12 in Solid TumorsFour Objective Responses Observed in Breast and Ovarian Cancers with CBX-12Dose-Limiting Toxicity Identified as...
Cybrexa Appoints Jaya Gautam as Senior Vice President of Technical Operations
12 avr. 2023 08h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., April 12, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Cybrexa Strengthens Drug Development Capabilities with the Addition of Laurie Kenvin to the Company’s Leadership Team and Nick Saccomano to the SAB
01 févr. 2023 08h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Cybrexa Therapeutics Announces the Appointment of Michael N. Needle, MD, as Senior Vice President and Chief Medical Officer
15 déc. 2022 07h00 HE
|
Cybrexa Therapeutics
NEW HAVEN, Conn., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...
Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium
28 oct. 2022 09h25 HE
|
Cybrexa Therapeutics
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...
Cybrexa Therapeutics Presents Findings from First-in-Human Study of CBX-12 as a Plenary Oral Presentation at 34th EORTC-NCI-AACR Symposium
28 oct. 2022 09h25 HE
|
Cybrexa Therapeutics
Positive FIH safety and tolerability data supports advancing CBX-12 into multiple Phase II studiesResults show early signs of efficacy with a favorable safety profile NEW HAVEN, Conn., Oct. 28, 2022...
The Market Will Be Driven By Entry Of New Products In The Market And Increasing Number Of Therapies In Clinical Trials Says Kuick Research
09 sept. 2022 05h44 HE
|
KuicK Research
Singapore, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Global Peptide Therapeutics Market & Clinical Trials Insight 2028 Report Findings: Global Peptide Therapeutics Market Opportunity > USD 75...
Global Peptide Drug Conjugate Antibody Market Forecast 2026
06 juil. 2021 08h34 HE
|
KuicK Research
DELHI, India, July 06, 2021 (GLOBE NEWSWIRE) -- Global Peptide Drug Conjugate Market & Clinical Trials Insight 2026 Report Highlights: First FDA Approved Peptide Drug Conjugate: Pepaxto...
Global Peptide Drug Conjugate Market Opportunity 2026 US Europe Japan South Korea Sales Forecast 2026
17 avr. 2021 05h09 HE
|
KuicK Research
DELHI, India, April 17, 2021 (GLOBE NEWSWIRE) -- Global Peptide Drug Conjugate Market and Clinical Trials Insight 2026 Report Highlights: First FDA Approved Peptide Drug Conjugate: Pepaxto...